$BMRN · BIOMARIN PHARMACEUTICAL INC SEC Filings
Position Tracker tracks 2 SEC EDGAR filings for BIOMARIN PHARMACEUTICAL INC ($BMRN) from November 2, 2026 through November 4, 2026, including 0 Form 10-K annual reports, 1 Form 10-Q quarterly earnings reports, 1 Form 8-K current event disclosures, and 0 Form 4 insider equity transactions. Select any filing below to read the full AI summary, key financial takeaways, and original SEC.gov document.
$BMRN 10-Q — BIOMARIN PHARMACEUTICAL INC
The Amicus acquisition has fundamentally reshaped BioMarin's financial profile — revenue doubled in scale but the company is now deeply leveraged with a transformed balance shee…
$BMRN 8-K — BIOMARIN PHARMACEUTICAL INC
A ~40% EPS guidance cut from a $11B+ rare-disease leader, even alongside a milestone $1B revenue quarter, signals that acquisition integration costs are overwhelming top-line mo…